- Maryland AG Anthony Brown has announced settlements with seven opioid drug manufacturers including Alvogen, Amneal, Apotex, Hikma, Mylan, Sun, and Zydus. Maryland is expected to receive over $13 million from the multistate settlement.
- The AGs alleged that for decades these seven companies have manufactured and sold generic opioids including oxycodone, hydrocodone, and fentanyl patches throughout the U.S., and that each of these manufacturers’ practices in manufacturing, selling, or marketing opioids resulted in significant diversion of opioids, contributing to the nationwide opioid crisis.
- Each settlement requires payments and imposes a set of injunctive terms on the manufacturers’ opioid business. The companies are prohibited from promoting or marketing opioid products to prescribers or patients, barred from manufacturing, promoting, or distributing any oxycodone pill exceeding 40 milligrams and barred from tying sales staff pay or discipline to opioid sales volume. Each company must also maintain an ongoing system to monitor and report suspicious orders of its opioid products.